183619-38-7
183619-38-7
Chemical Structure
CPI-1189
- CAS No.: 183619-38-7
- Formula:C13H18N2O2
- Molecular Weight:234.29
IUPAC Name: 4-acetamido-N-(tert-butyl)benzamide
InChIKey: DJKNRCWSXSZACF-UHFFFAOYSA-N
SMILES: O=C(NC(C)(C)C)C1=CC=C(NC(C)=O)C=C1
Biological Activity: CPI-1189 is an orally active TNF-α release inhibitor. CPI-1189 inhibits phosphorylation of p38. CPI-1189 can inhibit apoptosis. CPI-1189 can be used in the study of HIV and neurological diseases[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CPI-1189 | 99.82% | CPI-1189 is an orally active TNF-α release inhibitor. CPI-1189 inhibits phosphorylation of p38. CPI-1189 can inhibit apoptosis. CPI-1189 can be used in the study of HIV and neurological diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Müller T. CPI-1189. Centaur. Curr Opin Investig Drugs. 2002 Dec;3(12):1763-7. [Content Brief]
- [2]. Clifford DB, et al. A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology. 2002 Nov 26;59(10):1568-73. [Content Brief]
- [3]. Li YJ, et al. CPI-1189 protects neuronal cells from oxygen glucose deprivation/re-oxygenation-induced oxidative injury and cell death. Aging (Albany NY). 2021 Feb 17;13(5):6712-6723. [Content Brief]
- [4]. Hensley K, et al. CPI-1189 inhibits interleukin 1beta-induced p38-mitogen-activated protein kinase phosphorylation: an explanation for its neuroprotective properties? Neurosci Lett. 2000 Mar 10;281(2-3):179-82. [Content Brief]
- [5]. Bjugstad KB, et al. Preventive actions of a synthetic antioxidant in a novel animal model of AIDS dementia. Brain Res. 1998 Jun 8;795(1-2):349-57. [Content Brief]
